Document Detail

Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients.
MedLine Citation:
PMID:  23059959     Owner:  NLM     Status:  Publisher    
BackgroundThe purpose of this study is to characterize the risk factors of bloodstream infection (BSI) associated with the use of permanent implantable venous ports (Port-A) in solid cancer patients.MethodsSolid cancer patients implanted with a Port-A were prospectively observed for the occurrence of Port-A-associated BSI (PABSI), defined as BSI without other identifiable infection foci. A PABSI risk score was developed using the Cox proportional hazards model.ResultsA total of 415 patients were registered; 88 PABSI episodes occurred in 58 patients (incidence1.05 per 1000 catheter-days). All but one patient had stage IV cancer. Independent predictors of PABSI occurrence included neutropenia, total parenteral nutrition (TPN), chronic steroid use, invasive procedures, postoperative antibiotics, and preoperative antibiotics. A PABSI risk score with a cut-off value of 0 (sensitivity 88.5%, specificity 64.3%) was defined for stage IV cancer patients as follows: neutropenia, +1.350; TPN, +1.256; chronic steroid use, +1.947; preoperative antibiotics, -0.970; postoperative antibiotics, +0.959; and invasive procedures, +1.098. The median PABSI-free survival was 4.47 months for patients with scores ≥0 but not reached for patients with scores <0 (P < 0.0001).ConclusionThe PABSI risk score can assist in identifying high-risk solid cancer patients and may assist in designing future preventive strategies.
I C Chen; C Hsu; Y C Chen; S F Chien; H F Kao; S Y Chang; F C Hu; K H Yeh
Related Documents :
16526989 - Prostate sparing radical cystectomy--not for all, but an option for some.
17461539 - Robot-assisted laparoscopic radical prostatectomy: four cases.
18501409 - Fertility preservation in patients with early cervical cancer: radical trachelectomy.
10210369 - Molecular determination of surgical margins using fossa biopsies at radical prostatectomy.
22122479 - Genomics and cancer drug resistance.
16813889 - Detectable prostate specific antigen between 60 and 120 days following radical prostate...
15533909 - Brca1 and brca2 mutations in a study of african american breast cancer patients.
16526989 - Prostate sparing radical cystectomy--not for all, but an option for some.
9840109 - Possibility of different cancer development between the proximal and distal colon: comp...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-11
Journal Detail:
Title:  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO     Volume:  -     ISSN:  1569-8041     ISO Abbreviation:  Ann. Oncol.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007735     Medline TA:  Ann Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Oncology, National Taiwan University Hospital, Taipei.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer.
Next Document:  Haemodynamic effects from aortocaval compression at different angles of lateral tilt in non-labourin...